Amgen Inc.
High titer recombinant AAV vector production in adherent and suspension cells

Last updated:

Abstract:

The present invention is directed to an in vitro method of producing a recombinant AAV virion in a mammalian host cell that comprises a functional adenoviral E1A gene and rAAV virions made by the method. Host cells are transfected with varying ratios of plasmids comprising the E1A gene and virions.

Status:
Grant
Type:

Utility

Filling date:

28 Aug 2014

Issue date:

3 Aug 2021